Show simple item record

dc.contributor.authorBergström, Tomi
dc.contributor.authorTaskila, Jyri J.
dc.contributor.authorAlakare, Birgitta
dc.contributor.authorKöngäs-Saviaro, Päivi
dc.contributor.authorMiettunen, Jouko
dc.contributor.authorSeikkula, Jaakko
dc.date.accessioned2020-10-13T08:29:55Z
dc.date.available2020-10-13T08:29:55Z
dc.date.issued2020
dc.identifier.citationBergström, T., Taskila, J. J., Alakare, B., Köngäs-Saviaro, P., Miettunen, J., & Seikkula, J. (2020). Five-Year Cumulative Exposure to Antipsychotic Medication After First-Episode Psychosis and its Association With 19-Year Outcomes. <i>Schizophrenia Bulletin Open</i>, <i>1</i>(1), Article sgaa050. <a href="https://doi.org/10.1093/schizbullopen/sgaa050" target="_blank">https://doi.org/10.1093/schizbullopen/sgaa050</a>
dc.identifier.otherCONVID_42490833
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/72129
dc.description.abstractThe long-term effectiveness of antipsychotic maintenance treatment after first-episode psychosis (FEP) is contested. In this real-world observational study, we examined how cumulative exposure to antipsychotics within the first 5 years from FEP was associated with the 19-year outcome. Finnish national registers were used to detect all patients who were hospitalized due to non-affective psychosis in the mid-1990s, and who were treatment naïve prior to the inclusion period (N = 1318). Generalized linear models with logit link function were used to estimate how cumulative exposure to antipsychotics within the first 5 years from onset was associated with mortality, work capability, and the use of psychiatric services at the end of the 19-year follow-up. To adjust for confounding by indication, the primary outcome analyses implemented stabilized inverse probability of treatment weighting using propensity scores. Persons with a higher cumulative exposure to antipsychotics within the first 5 years from FEP were more likely to still be receiving antipsychotics (adjusted odds ratio [OR] = 2.1; 95\\% CI: 1.5−2.8), psychiatric treatment (OR = 1.4; 95\\% CI: 1.1−1.7), and disability allowances (OR = 1.3; 95\\% CI: 1.01−1.6) at the end of the 19-year follow-up, as compared to low/zero-exposure. Higher cumulative exposure was also associated with higher mortality (OR = 1.5; 95\\% CI: 1.1–2.1). After adjustment for confounders, moderate and high cumulative exposure to antipsychotics within the first 5 years from FEP was consistently associated with a higher risk of adverse outcomes during the 19-year follow-up, as compared to low or zero exposure. Due to potential unmeasured confounding, controlled trials are needed.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherOxford University Press (OUP)
dc.relation.ispartofseriesSchizophrenia Bulletin Open
dc.rightsCC BY-NC 4.0
dc.titleFive-Year Cumulative Exposure to Antipsychotic Medication After First-Episode Psychosis and its Association With 19-Year Outcomes
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202010136187
dc.contributor.laitosPsykologian laitosfi
dc.contributor.laitosDepartment of Psychologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.description.reviewstatuspeerReviewed
dc.format.pagerangeIn Progress
dc.relation.issn2632-7899
dc.relation.numberinseries1
dc.relation.volume1
dc.type.versionpublishedVersion
dc.rights.copyright© The Author(s) 2020. Published by Oxford University Press on behalf of the University of Maryland's school of medicine, Maryland Psychiatric Research Center
dc.rights.accesslevelopenAccessfi
dc.subject.ysomielenterveyshäiriöt
dc.subject.ysotyökyky
dc.subject.ysopsykiatrinen hoito
dc.subject.ysoylläpitohoito
dc.subject.ysopsyykenlääkkeet
dc.subject.ysoskitsofrenia
dc.subject.ysolääkehoito
dc.subject.ysokohorttitutkimus
dc.subject.ysopsykoosit
dc.subject.ysokuolleisuus
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p990
jyx.subject.urihttp://www.yso.fi/onto/yso/p10214
jyx.subject.urihttp://www.yso.fi/onto/yso/p7915
jyx.subject.urihttp://www.yso.fi/onto/yso/p25321
jyx.subject.urihttp://www.yso.fi/onto/yso/p7977
jyx.subject.urihttp://www.yso.fi/onto/yso/p9659
jyx.subject.urihttp://www.yso.fi/onto/yso/p10851
jyx.subject.urihttp://www.yso.fi/onto/yso/p25606
jyx.subject.urihttp://www.yso.fi/onto/yso/p4145
jyx.subject.urihttp://www.yso.fi/onto/yso/p5003
dc.rights.urlhttps://creativecommons.org/licenses/by-nc/4.0/
dc.relation.doi10.1093/schizbullopen/sgaa050
jyx.fundinginformationSupported in part by Finnish State Research Funding (VTR), granted by the Ministry of Social Affairs and Health, Finland. The funding source had no involvement in the design, collection, analysis, or interpretation of the date.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY-NC 4.0
Except where otherwise noted, this item's license is described as CC BY-NC 4.0